These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31832822)

  • 1. Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration.
    Lee CF; Zhou K; Young WM; Wong CS; Ng TY; Lee SF; Leung K; Wong LKM; So KH; Tang W; Chong G; Chan SK; Yip YTE; Ma VYM; Yeung A; Chin CHY; Kwan MW; Tsang HT
    Support Care Cancer; 2020 Aug; 28(8):3801-3812. PubMed ID: 31832822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
    Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
    Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
    Lee EK; Wong WW; Trudeau ME; Chan KK
    Breast Cancer Res Treat; 2015 Feb; 150(1):169-80. PubMed ID: 25694355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
    Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
    Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
    Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
    Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
    Agiro A; Ma Q; Acheson AK; Wu SJ; Patt DA; Barron JJ; Malin JL; Rosenberg A; Schilsky RL; Lyman GH
    J Clin Oncol; 2016 Nov; 34(32):3872-3879. PubMed ID: 27646945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
    Assi H; Murray J; Boyle L; Rayson D
    Support Care Cancer; 2014 Dec; 22(12):3227-34. PubMed ID: 24996828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.
    Poon DMC; Chan K; Chan TW; Ng B; Siu S; Ng J; Johnson D; Lee KC;
    Asia Pac J Clin Oncol; 2021 Apr; 17 Suppl 3():39-47. PubMed ID: 33860642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of the Incidence of Febrile Neutropenia in Doxorubicin/Cyclophosphamide(AC)and Docetaxel/Cyclophosphamide(TC) Perioperative Chemotherapies for Primary Breast Cancer].
    Nohara Y; Ono S; Tanaka M; Yoshinaga Y; Ito T; Yamashita S; Iwasaki A
    Gan To Kagaku Ryoho; 2020 Nov; 47(11):1589-1591. PubMed ID: 33268733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy.
    Blayney DW; Kuderer NM; Cummings Joyner AK; Jarvis J; Nunag D; Wells J; Huang L; Mohanlal R; Lyman GH
    J Natl Compr Canc Netw; 2023 Sep; 21(9):945-950.e16. PubMed ID: 37673111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.
    Bacrie J; Laurans M; Iorio P; Fourme E; Volters AB; Bozec L; Lerebours F; Dubot C; Bensaoula O; Benzidane B; Pierga JY; Lefeuvre D
    Support Care Cancer; 2018 Dec; 26(12):4097-4103. PubMed ID: 29855772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
    van Dooijeweert C; van der Wall E; Baas IO
    Neth J Med; 2019 Dec; 77(9):310-316. PubMed ID: 31814585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
    Gerlier L; Lamotte M; Awada A; Bosly A; Bries G; Cocquyt V; Focan C; Henry S; Lalami Y; Machiels JP; Mebis J; Straetmans N; Verhoeven D; Somers L
    BMC Cancer; 2010 Nov; 10():642. PubMed ID: 21092320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
    Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
    Zekri J; Nawaz A; Rasool H; Ahmad I; Abdel Rahman H; Dada R; Abdelghany EM; Farag K; Ibrahim RB; Deibas MY; Kamel MK; Allithy A
    J Oncol Pharm Pract; 2022 Dec; 28(8):1681-1686. PubMed ID: 34342555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
    Ngamphaiboon N; O'Connor TL; Advani PP; Levine EG; Kossoff EB
    Med Oncol; 2012 Sep; 29(3):1495-501. PubMed ID: 21818673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
    Fernandes R; Mazzarello S; Stober C; Vandermeer L; Dudani S; Ibrahim MF; Majeed H; Perdrizet K; Shorr R; Hutton B; Fergusson D; Clemons M
    Breast Cancer Res Treat; 2017 Jan; 161(1):1-10. PubMed ID: 27783280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.
    Chan A; Fu WH; Shih V; Coyuco JC; Tan SH; Ng R
    Support Care Cancer; 2011 Apr; 19(4):497-504. PubMed ID: 20232087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.